CRB, a prominent provider of engineering, architecture, construction, and consulting services for the life sciences and food and beverage sectors, has recently named Eric Hanson as Senior Director in its Life Sciences division. With over 20 years of experience in biotechnology operations, facility design, and manufacturing, Hanson brings a wealth of expertise to CRB’s expanding project portfolio. His appointment aims to enhance the company’s capabilities in guiding clients through the complexities of advanced therapy manufacturing strategies and executing the design and construction of facilities tailored for the production of cutting-edge therapeutics.
Hanson’s background includes leadership roles at Kite Pharma and Gilead Sciences, where he oversaw manufacturing operations for retroviral and lentiviral vectors. Noteworthy achievements include driving operational readiness, implementing quality and safety measures, and reducing deviation rates through the application of LEAN principles. His experience covers the entire lifecycle of cGMP facilities, from design and commissioning to regulatory inspections and commercial production. Additionally, Hanson has led strategic initiatives to ensure uninterrupted clinical supply chains, even during challenging periods such as the global COVID-19 pandemic.
Having a Master of Business Administration and a Bachelor of Science in Nuclear Engineering Technology, Hanson’s expertise extends to operational management, engineering, validation, and regulatory compliance in the biologics industry. His proven track record in overseeing the design and construction of state-of-the-art manufacturing facilities aligns with CRB’s commitment to delivering high-quality, efficient, and compliant spaces for advanced therapy production. Hanson’s appointment underscores CRB’s dedication to providing clients with the necessary leadership and guidance to navigate the evolving landscape of biotechnology manufacturing.
CRB’s Vice President of Life Sciences, Noel Maestre, expressed confidence in Hanson’s appointment, highlighting his executive leadership skills and ability to navigate complex phases of capital project delivery and operational readiness. By leveraging Hanson’s experience in facility design, GMP compliance, and regulatory preparedness, CRB aims to bolster its position as a trusted partner for clients seeking rapid and reliable development of advanced therapy facilities. Hanson’s addition to the leadership team signifies CRB’s strategic focus on enhancing its offerings in response to the increasing demand for cutting-edge biotechnology solutions.
As a seasoned professional in the biotechnology industry, Hanson’s appointment at CRB represents a strategic move to strengthen the company’s expertise in advanced therapy manufacturing. With a strong background in operational excellence, facility design, and regulatory compliance, Hanson is well-positioned to drive CRB’s efforts in delivering fit-for-purpose facilities that enable the safe and efficient production of next-generation therapeutics. His proven leadership in navigating the complexities of biologics manufacturing reinforces CRB’s commitment to providing world-class solutions that drive success and positive change for its clients and communities.
Key Takeaways:
– Eric Hanson’s appointment as Senior Director at CRB’s Life Sciences division enhances the company’s leadership in advanced therapy manufacturing.
– Hanson’s extensive experience in biotechnology operations, facility design, and regulatory compliance strengthens CRB’s capabilities in delivering cutting-edge therapeutic production facilities.
– CRB’s strategic focus on appointing industry veterans like Hanson underscores its commitment to providing clients with high-quality, efficient, and compliant solutions in the evolving biotechnology landscape.
Tags: biotech, regulatory, process development, lentiviral vectors, validation
Read more on finance.yahoo.com